Risk that R&D and capital investment fail to result in commercialization
First written in FY2017. 3 of 9 entries say "Restated". Latest entry: 2026-03-09.
Miraial moved to the "Worse" side of this theme in 2023, 1 year before the typical company in this theme (2024).
The whole theme swung hardest in 2026: 19 of 24 companies on the "Worse" side.
26 other companies' latest entry also says "Materialised".
- 2026-03-09MaterialisedRevision of earnings forecasts
「Because the above assets became idle assets, their carrying amounts were reduced to recoverable value, and the reductions were recorded as impairment losses under extraordinary losses.」
An impairment loss of ¥20.903 million was recorded again during the current fiscal year for molds that were idle assets in Kikuchi, Kumamoto Prefecture. - FY2025MitigatedAnnual report
「The Group recorded an impairment loss of ¥15 million during the consolidated fiscal year.」
Impairment losses associated with declining profitability of idle assets amounted to ¥15 million, down from ¥81.396 million in the previous fiscal year. Risks relating to the commercialization and profitability of equipment and assets remain, but the loss was smaller than in the previous fiscal year. - FY2024MaterialisedAnnual report
「During the consolidated fiscal year, the carrying amounts of idle assets were reduced to their recoverable amounts because their profitability had declined, and the reductions were recorded as impairment losses under extraordinary losses.」
The Group recorded total impairment losses of ¥81.396 million on machinery and transportation equipment in Fukushima, Fukushima Prefecture; buildings and structures in Hanno, Saitama Prefecture; and molds in Kikuchi, Kumamoto Prefecture. As in the previous fiscal year, declining profitability of equipment and assets materialized as actual accounting losses. - FY2023MaterialisedAnnual report
「During the consolidated fiscal year, the carrying amounts of idle assets were reduced to their recoverable amounts because their profitability had declined, and the reductions were recorded as impairment losses under extraordinary losses.」
The Group recorded an impairment loss of ¥222.397 million on molds that were idle assets because their profitability had declined. The risk of impairment if research and development and capital investment fail to lead to commercialization materialized as an actual accounting loss. - FY2022RestatedAnnual report
「The Group is taking steps to avoid risks through appropriate review and approval procedures. However, if a business fails to get off the ground despite the investment of research and development expenses and capital expenditures, the Group’s performance could be affected.」
The advance investment in research and development expenses and capital expenditures, and the impact on performance if the business fails to get off the ground, continued to be disclosed. - FY2021ReframedAnnual report
「If demand for products related to capital investments falls significantly below expectations, the resulting excessive depreciation burden, disposal of equipment and impairment losses could affect the Group’s performance.」
In addition to the existing risk that research and development and capital investment may not lead to commercialization, the potential impact of capital investment risk was clarified: excessive depreciation, equipment disposals and impairment losses if product demand falls below expectations. - FY2019RestatedAnnual report
「The Group incurs research and development expenses and capital expenditures in advance to strengthen its existing businesses and develop new businesses. Accordingly, if a business fails to get off the ground despite these investments, the Group’s performance could be affected.」
The advance investment in research and development expenses and capital expenditures, and the impact on performance if the business fails to get off the ground, continued to be disclosed as risks. - FY2018RestatedAnnual report
「The Group incurs research and development expenses and capital expenditures in advance to strengthen its existing businesses and develop new businesses. Accordingly, if a business fails to get off the ground despite these investments, the Group’s performance could be affected.」
The advance investment in research and development expenses and capital expenditures, and the impact on performance if the business is not commercialized, continued to be disclosed as risks. - FY2017First statedAnnual report
「The Group incurs research and development expenses and capital expenditures in advance to strengthen its existing businesses and develop new businesses. Accordingly, if a business fails to get off the ground despite these investments, the Group’s performance could be affected.」
The impact on performance if a business into which research and development expenses and capital expenditures have been invested in advance fails to get off the ground was disclosed as a risk.